CytRx Corporation (NASDAQ:CYTR) Under Investor Scanner

812

Dallas, Texas 03/31/2014 (FINANCIALSTRENDS) – CytRx Corporation (NASDAQ:CYTR), the Los- Angeles based cancer treatment developer has surprisingly come under the scanner for misleading investors. CytRx Corporation (NASDAQ:CYTR) is currently under investigation by Cohen Milstein Sellers & Toll PLLC, to find out if there was intentional misleading by executives and office bearers of the organization. The sections for which the investigations are being conducted are: Sections 10(b), 20(a) of the Securities Exchange Act of 1934.

CytRx Corporation (NASDAQ:CYTR) holds a market cap of $190.59 million and also holds an average trading volume of 2.68million. The company has in the previous trading session opened stocks at prices of $3.20, while the price of this stock ranged between $3.19 and $3.49. The company has also posted 52 week high of 8.35 and 1.95 low. EPS has been -1.34 and the outstanding shares have been 55.56 million. Beta is 1.49.

CytRx Corporation (NASDAQ:CYTR) specializes in the preparation of medicines to treat cancer. As one of the leading companies involved in this sector, it holds a long-line of products which are known to provide relief in this sector. The first is the INNO-206, tamibarotene as well as bafetinib. It has to benoted that INNO-20 targets tumor with the doxorubicin conjugate.

CytRx Corporation (NASDAQ:CYTR) has previously sold the intellectual property rights of this to Orphazyme Aps in 2011.

CYTR currently has competitor such as, Ariad Pharmaceuticals, Johnson & Johnson Merck & Co., as well as Cell Therapeutics, GlaxoSmithKline, besides Sanofi-Aventis.

CYTR has also been in the news for paid promotions. Along with GALE, the company has been under investigations for unprecedented gains the company had- an increase of nearly four times, due to a behind the seam 100 Dream Team articles.

Investors were apparently lured by contents of the newsletters which led to the gains made by both GALE as well as CTRY.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.